Inflammatory bowel disease
Conditions
Interventions
Combined treatment group:Mesalazine + Andrographolide
Conventional treatment group:Mesalazine
Sponsors
Huai'an First People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1: Chinese guidelines for the diagnosis and treatment of ulcerative colitis (2023 Xi'an) in adult patients with a clear diagnosis of mild to moderate active ulcerative colitis; 2: After fully assessing the risks/benefits physicians prescribe andrographolide to adults with ulcerative colitis; 3: Patients with mildly or moderately active ulcerative colitis 3 points = modified Mayo score = 10 points.and endoscopic finding score = 2; 4: Patients and must sign an informed consent form and study protocols/informed consent forms used for data collection data validation should comply with legal and regulatory requirements.
Exclusion criteria
Exclusion criteria: 1: Based on the Andrographolide instructions and the judgment of the treating physician the patient is not suitable for treatment with Andrographolide; 2: Those with organic intestinal pathology and significant complications; 3: Have severe primary cardiovascular lesions liver function exceeding 1.5 times the upper limit of normal abnormal renal function hematological lesions pulmonary disease or a serious illness that affects their survival 4: Patients who are participating in other clinical studies; 5: Patients who in the opinion of the investigator are not suitable for participation in this trial.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Change in SCCAI scores from baseline levels at weeks 4 and 8; | — |
Countries
China
Contacts
Public ContactHonggang Wang
Huai'an First People's Hospital
Outcome results
None listed